With Organic Nitrogen Containing Compound Patents (Class 514/162)
-
Publication number: 20140154314Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20140147448Abstract: The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk.Type: ApplicationFiled: June 5, 2012Publication date: May 29, 2014Applicant: Yale UniversityInventors: John Hwa, WaiHo Tang
-
Publication number: 20140148418Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Applicant: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20140134261Abstract: The present invention relates to pharmaceutical compositions comprising ester(s) of capsaicin and at least one other agent selected from salicylates, menthol, boswellic acids, DMSO, methyl sulfonylmethane, NSAIDs, corticosteroids, emu oil, opioid agonists and antagonists, NMDA antagonists, tramadol, hyaluronic acid, ?2? ligands, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice, for improved therapeutic properties. Further, the present invention relates to pharmaceutical compositions comprising high concentrations of ester(s) of capsaicin. Further, the present invention relates to a method of relieving pain due to various diseases in subjects by administering the pharmaceutical compositions of the invention.Type: ApplicationFiled: August 21, 2013Publication date: May 15, 2014Applicant: Trinity Laboratories, Inc.Inventors: Chandra U. Singh, David L. Woody, Rao Nulu Jagaveerabhadra
-
Patent number: 8709454Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.Type: GrantFiled: January 12, 2010Date of Patent: April 29, 2014Assignee: L'OrealInventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
-
Publication number: 20140086854Abstract: The invention relates to water-soluble or water-swellable polymers that contain a) 20.0 to 98.97 mole-% of one or more repeating structural units originating from special monomers with sulfonic acid groups or the salts thereof such as e.g. 2-acrylamido-2-methyl-propanesulfonic acid or the salts thereof, b) 1.0 to 60.0 mole-% of one or more repeating structural units containing an amide group and d) 0.01 to 8.0 mole-% of one or more repeating structural units originating from special crosslinking agents with at least three polymerizable double bonds. The polymers for example have an advantageous sensory property profile and are highly suitable as thickening agents even in salt-containing compositions. They are furthermore advantageously suitable for producing cosmetic, dermatological or pharmaceutical compositions.Type: ApplicationFiled: March 3, 2012Publication date: March 27, 2014Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Peter Klug, Dirk Fischer, Thomas Lindner, Wiebke Mueckenheim, Bianca Brasch, Michael Hornung
-
Publication number: 20140073612Abstract: A transdermal delivery kit that enhances the efficacy of a topical drug includes at least one drug dispensing device, a lipophilic base, a hydrophilic base, a lipid-soluble active ingredient, a water-soluble active ingredient, a first container for mixing the lipophilic base with the lipid-soluble active ingredient to form a first compound, a second container for mixing the hydrophilic base with the water-soluble active ingredient to form a second compound, a mixing member, and instructions for compounding the lipophilic base with the lipid-soluble active ingredient to form the first compound, compounding the hydrophilic base with the water-soluble active ingredient to form the second compound, and mixing the first compound and the second compound to form a transdermal pharmaceutical delivery system capable of delivering a drug to the dermal layer of the skin.Type: ApplicationFiled: September 11, 2012Publication date: March 13, 2014Inventors: Carlos A. Alfaras, Paul M. Zimmerman, Urbano Zamora
-
Publication number: 20140073613Abstract: The present invention relates in general to topical compositions having improved antimicrobial effect useful for the treatment of hyperkeratotic skin conditions. More specifically, the present invention relates to topical compositions comprising a combination of one or more alfa-hydroxy acids, urea, glycerol, and panthenol, as well as the use of such compositions for the treatment of hyperkeratotic skin conditions, in particular on the feet, and also on other body areas where thick skin is noted and where infections should be avoided.Type: ApplicationFiled: May 14, 2012Publication date: March 13, 2014Inventors: Johan Sundbom Nilsson, Marie Lodén
-
Patent number: 8629127Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: November 28, 2012Date of Patent: January 14, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Patent number: 8623847Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: May 3, 2012Date of Patent: January 7, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20130345183Abstract: A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: ApplicationFiled: August 14, 2013Publication date: December 26, 2013Applicant: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20130336902Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
-
Publication number: 20130261091Abstract: A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel.Type: ApplicationFiled: March 8, 2013Publication date: October 3, 2013Applicant: ESSENTIAL INGREDIENTS, INC.Inventors: Chris Gerlach, Mike Davies
-
Publication number: 20130252925Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: API Genesis, LLCInventors: Daniel Bucks, Philip J. Birbara
-
Publication number: 20130251814Abstract: The present invention discloses a magnetic nanodrug for treating thrombosis, which comprises a core formed of magnetic nanoparticles, a shell enveloping the core and made of carboxyl-functionalized polyaniline, and a thrombosis-treatment drug covalently bonded to the shell. The magnetic nanodrug of the present invention is non-toxic to vascular endothelial cells, has superior stability, features superparamagnetism, and can be uniformly dissolved in water. Therefore, the magnetic nanodrug for treating thrombosis can be guided by an external magnetic field to concentrate on a specified region and increase the effect of thrombosis treatment.Type: ApplicationFiled: September 14, 2012Publication date: September 26, 2013Inventors: Mu-Yi Hua, Hung-Wei Yang, Tony Wu, Rung-Ywan Tsai, Yunn-Hwa Ma, Jyh-Ping Chen
-
Patent number: 8541398Abstract: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.Type: GrantFiled: February 11, 2010Date of Patent: September 24, 2013Assignee: Antibe Therapeutics Inc.Inventors: John L. Wallace, Giuseppe Cirino, Vincenzo Santagada, Giuseppe Caliendo
-
Publication number: 20130225538Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: ETHICON, INC.Inventor: ETHICON, INC.
-
Publication number: 20130216620Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 20, 2013Publication date: August 22, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Patent number: 8507006Abstract: Individualized porous particles having a volume-average diameter of less than or equal to 10 ?m and a specific surface area of greater than or equal to 1 m2/g, and that include at least one cosmetically or pharmaceutically active compound present at least inside the particles.Type: GrantFiled: December 5, 2011Date of Patent: August 13, 2013Assignee: L'OrealInventors: Jean-Thierry Simonnet, Bruno Biatry, Didier Saint-Leger
-
Publication number: 20130196956Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Publication number: 20130189335Abstract: The present invention provides an oil-in-water emulsified composition comprising the following ingredients (A)-(G) characterized by miniaturization of the emulsified particles by means of high pressure emulsification: (A) salt type drug (B) hydrophilic nonionic surfactant (C) N-long chain acyl acidic amino acid mono salt (D) two or more types of higher fatty acids and alkali that constitutes higher fatty acid soap (E) higher alcohol (F) oil component (G) water. The object of the present invention is to provide an oil-in-water emulsified composition prepared by miniaturizing emulsified particles by means of a high pressure emulsification method, said composition being superior in terms of emulsification stability such that electrolyte salt type drugs can be stably blended in.Type: ApplicationFiled: October 4, 2011Publication date: July 25, 2013Applicant: SHISEIDO COMPANY, LTD.Inventor: Takumi Watanabe
-
Publication number: 20130157985Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.Type: ApplicationFiled: September 10, 2012Publication date: June 20, 2013Applicant: API GENESIS, LLCInventors: Daniel BUCKS, Philip J. BIRBARA
-
Patent number: 8445015Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: GrantFiled: July 27, 2012Date of Patent: May 21, 2013Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Publication number: 20130123218Abstract: A method of treatment using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: ApplicationFiled: January 2, 2013Publication date: May 16, 2013Applicant: THEAPRIN PHARMACEUTICALS INC.Inventor: THEAPRIN PHARMACEUTICALS INC.
-
Publication number: 20130101615Abstract: This invention is a method for immunizing, preventing or treating a Mycobacterium avium subspecies paratuberculosis-associated disease or condition by screening subjects for markers indicative of predisposition or susceptibility to a Mycobacterium avium subspecies paratuberculosis-associated disease or condition and administering a Mycobacterium avium subspecies paratuberculosis vaccine or prophylactic or therapeutic agent.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Inventor: Robert J. Greenstein
-
Publication number: 20130096093Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: ApplicationFiled: November 28, 2012Publication date: April 18, 2013Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMAInventor: The Board of Regents of the University of Oklahom
-
Publication number: 20130059801Abstract: The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.Type: ApplicationFiled: August 31, 2012Publication date: March 7, 2013Applicant: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu, Amal Ting
-
Publication number: 20130035316Abstract: This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia.Type: ApplicationFiled: December 30, 2010Publication date: February 7, 2013Applicant: BCWORLD PHARM. CO., LTD.Inventors: Hearan Suh, Myungkwan Chun, Taekun An, Juhuen Choi, Hyunmi Seo, Jisung Lim, Choongho Ryu, Jeong Ku, Youngdai Seo, Younji Shin, Junhee Lee
-
Publication number: 20130012482Abstract: A water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: THEAPRIN PHARMACEUTICALS INC.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20130005683Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.Type: ApplicationFiled: June 8, 2012Publication date: January 3, 2013Inventor: Jallal Messadek
-
Publication number: 20120328544Abstract: A dermatological composition for application to the skin or nails comprises a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moiety, a guanidine moiety or a biguanide moiety. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moiety. The composition may be prepared by a metathesis or acid-base reaction.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: Nevada Naturals, Inc.Inventors: Richard F. Stockel, Anthony J. Sawyer, Anthony E. Winston
-
Publication number: 20120302528Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.Type: ApplicationFiled: August 6, 2012Publication date: November 29, 2012Applicant: ETHICON, INC.Inventors: Sasa ANDJELIC, Benjamin D. FITZ, Jianguo Jack ZHOU
-
Publication number: 20120294943Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Applicant: Wellesley Pharmaceuticals, LLCInventor: David A. DILL
-
Patent number: 8309538Abstract: A method for cleansing and treating skin exposed to a capsaicin or derivative thereof so as to inhibit capsaicin reactivation includes: providing a subject having exposure to capsaicin, oleoresin capsicum, or other capsaicinoid derivative; cleansing capsaicin, oleoresin capsicum, or other capsaicinoid derivative from skin of the subject with a cleansing composition having: a carrier; a surfactant and/or detergent; a chelating agent; and salicylic acid, acetylsalicylic acid, or ibuprofen; and treating the skin of the subject with a therapeutic composition so as to inhibit reactivation of effects of capsaicin, oleoresin capsicum, or other capsaicinoid derivative exposure, the therapeutic composition having: a carrier; aloe; a thickening agent; and salicylic acid, acetylsalicylic acid, or ibuprofen.Type: GrantFiled: December 9, 2009Date of Patent: November 13, 2012Assignee: Kapso, LLCInventor: Christopher A. Reilly
-
Publication number: 20120244221Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Patent number: 8268805Abstract: The invention relates to the use, as agent for depigmenting and/or whitening the skin, in particular for eliminating pigmentary spots and/or senescence spots, and/or as anti-browning agents, of a compound of formula (I): R1—CHOH—CH(NH—COR2)(CH2OH)??(I) in which R1 denotes a C11 to C21 alkyl radical, and R2 denotes a linear, optionally hydroxylated C11-C19 hydrocarbon-based radical, with the hydroxyl group being in the alpha-position with respect to the carbonyl, which may comprise one or more ethylenic unsaturations, in particular one or two ethylenic unsaturations. The invention also relates to a cosmetic process for depigmenting and/or lightening skin exhibiting pigmentation spots, comprising the application to the skin of a composition comprising, in a physiologically acceptable medium, a compound of formula (I).Type: GrantFiled: December 15, 2006Date of Patent: September 18, 2012Assignee: L'OrealInventors: Pascale Pelletier, Catherine Marion
-
Publication number: 20120219610Abstract: Antimicrobial bar compositions can include, for example, from about 0.1% to about 35%, by weight of the antimicrobial bar composition, of water; from about 45% to about 99%, by weight of the antimicrobial bar composition, of soap; and from about 0.01% to about 5%, by weight of the antimicrobial bar composition, of platelet zinc pyrithione (“platelet ZPT”). The platelet ZPT includes a median particle diameter of about 2 microns to about 3 microns, a mean particle diameter of about 3 microns to about 4 microns, and a thickness of about 0.6 microns to about 15 microns.Type: ApplicationFiled: February 28, 2011Publication date: August 30, 2012Inventors: Edward Dewey Smith, III, Jason Edward Cook, Brian Joseph Limberg
-
Publication number: 20120214772Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: ApplicationFiled: May 3, 2012Publication date: August 23, 2012Applicant: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120190655Abstract: An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture.Type: ApplicationFiled: April 5, 2012Publication date: July 26, 2012Applicant: Theraprin Pharmaceuticals, Inc.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20120189684Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.Type: ApplicationFiled: July 19, 2010Publication date: July 26, 2012Applicant: Reckitt Benckiser Healthcare International LimitedInventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
-
Publication number: 20120189713Abstract: The invention relates to novel monomers of Formula (I) useful for preparation of phase-separated biocompatible polymers or polymer compositions. These polymers or polymer compositions may be bioresorbable and/or biodegradable and have desirable mechanical properties, such as fracture and/or fatigue toughness, which have not been a primary design criteria for such polymers previously. The polymers or polymer compositions are useful in a variety of medical applications, such as in the fabrication of medical devices. Therefore, methods for preparing these polymers or polymer compositions and medical devices are also encompassed by this disclosure.Type: ApplicationFiled: July 31, 2010Publication date: July 26, 2012Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Joachim B. Kohn, Durgadas Bolikal, Ramiro Rojas
-
Patent number: 8227451Abstract: The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: November 11, 2009Date of Patent: July 24, 2012Assignee: Auspex PharmaceuticalsInventors: Thomas G. Gant, Manouchehr M. Shahbaz
-
Publication number: 20120184513Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.Type: ApplicationFiled: January 14, 2011Publication date: July 19, 2012Applicant: Givaudan SAInventors: Andreas NATSCH, Michael WASESCHA
-
Patent number: 8211876Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: December 24, 2009Date of Patent: July 3, 2012Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120164192Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120164193Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120149666Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMAInventor: Richard F. HARTY
-
Publication number: 20120141554Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: January 4, 2012Publication date: June 7, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120135050Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: January 4, 2012Publication date: May 31, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20120128793Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 24, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian